medwireNews: Secukinumab provides sustained improvement in clinical and imaging outcomes in patients with psoriatic arthritis (PsA) and axial manifestations who have had an inadequate response to nonsteroidal anti-inflammatory drugs (NSAIDs), show 52-week data from the MAXIMISE trial.
The 12-week results, previously reported by medwireNews, showed that patients treated with the interleukin-17a inhibitor at a subcutaneous dose of 150 mg or 300 mg every 4 weeks were significantly more likely to achieve an ASA20 response than those treated with placebo, with rates of 86.9% and 63.4% versus 30.9% and 32.5%.
The corresponding findings for ASA40 response were 44.1% and 39.7% with secukinumab 300 mg and 150 mg versus 8.6% and 16.3% with placebo.
Presenting the latest results at the EULAR 2020 E-congress, Xenofon Baraliakos (Ruhr-University Bochum, Germany) reported that these responses rates were “sustained through week 52.”
At this timepoint, 81.3% of the 164 patients receiving secukinumab 300 mg from baseline had achieved an ASA20 response, as had 80.1% of 157 patients receiving the 150 mg dose.
And among the 322 patients who were re-randomized to secukinumab 300 mg (n=81) and 150 mg (n=80) after 12 weeks of placebo, the corresponding rates were 75.0% and 79.7%.
Similarly, 69.1% and 64.5% of patients receiving secukinumab 300 mg and 150 mg from baseline achieved an ASA40 response, as did 62.5% and 54.1% of those re-randomized.
Patients who were magnetic resonance imaging (MRI)-positive at baseline were also as likely to respond to secukinumab as those who were not. Among this group, 65.9% of patients given secukinumab 300 mg and 69.9% of those given the 150 mg dose achieved an ASA20 response at 12 weeks, compared with 27.4% of those given placebo.
Baraliakos noted that at baseline “the vast majority of the patients showed at least one or more features of inflammatory back pain.”
He presented 12-week data showing a 0.36–0.42 point reduction in the Total Berlin MRI score for the entire spine and a 0.55–0.61 point reduction for the sacroiliac joints, compared with little to no change with placebo and noted that these improvements “were sustained at week 52.”
Baraliakos confirmed that “overall, no new safety signals were reported through the entire treatment period.”
And he concluded: “Secukinumab provided significant and sustained improvement in the signs and symptoms and objective signs of inflammation of axial disease in patients with psoriatic arthritis with axial manifestations and inadequate response to NSAIDs.
“These results, we believe, will provide valuable data that will support the ASAS/GRAPPA efforts to deepen the clinical understanding of axial manifestations in psoriatic arthritis patients.”
medwireNews is an independent medical news service provided by Springer Healthcare. © 2020 Springer Healthcare part of the Springer Nature Group
EULAR 2020 E-Congress; 3–6 June
Ann Rheum Dis 2020; doi:10.1136/annrheumdis-2020-eular.638